# US 10,245,267 B2 · Biaryl amide compounds as kinase inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,245,267 B2
- Document ID: US10245267B2
- Status: Granted
- Kind: B2
- Application number: 15/601,423
- Filed: 2017-05-22
- Published: 2017-09-14
- Granted: 2019-04-02
- Earliest claimed: 2013-03-14
- Assignees: Novartis AG
- Applicants: Novartis AG
- Inventors: Robert John Aversa; Paul Andrew Barsanti; Matthew T. Burger; Michael Patrick Dillon; Alan Dipesa; Cheng Hu; Yan Lou; Gisele A. Nishiguchi; Yue Pan; Valery Rostislavovich Polyakov; Savithri Ramurthy; Alice C. Rico; Lina Quattrocchio Setti; Aaron Smith; Sharadha Subramanian; Benjamin R. Taft; Huw Roland Tanner; Lifeng Wan; Naeem Yusuff
- Web page: https://patentgrep.com/patent/US10245267B2

## CPC

- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/444: containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A61K 31/501: not condensed and containing further heterocyclic rings
- A61K 31/5375: 1,4-Oxazines, e.g. morpholine
- A61K 31/541: Non-condensed thiazines containing further heterocyclic rings
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07B 59/002: {Heterocyclic compounds}
- C07D 213/74: Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
- C07D 213/75: Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
- C07D 213/81: Amides; Imides
- C07D 213/82: in position 3
- C07D 213/84: Nitriles
- C07D 233/88: Nitrogen atoms, e.g. allantoin
- C07D 237/20: Nitrogen atoms (nitro radicals C07D237/12)
- C07D 237/22: Nitrogen and oxygen atoms
- C07D 237/24: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D 239/42: One nitrogen atom (nitro radicals C07D239/30)
- C07D 239/47: One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
- C07D 239/48: Two nitrogen atoms
- C07D 241/20: Nitrogen atoms (nitro radicals C07D241/16)
- C07D 263/58: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D 277/42: Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 401/14: containing three or more hetero rings
- C07D 403/04: directly linked by a ring-member-to-ring-member bond
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 405/04: directly linked by a ring-member-to-ring-member bond
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 405/14: containing three or more hetero rings
- C07D 409/14: containing three or more hetero rings
- C07D 413/04: directly linked by a ring-member-to-ring-member bond
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D 413/14: containing three or more hetero rings
- C07D 417/12: linked by a chain containing hetero atoms as chain links
- C07D 471/04: Ortho-condensed systems
- C07D 487/04: Ortho-condensed systems
- C07D 491/04: Ortho-condensed systems
- C07D 491/048: the oxygen-containing ring being five-membered
- C07D 491/08: Bridged systems
- C07D 491/107: with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D 493/04: Ortho-condensed systems
- C07D 493/10: Spiro-condensed systems
- C07D 495/04: Ortho-condensed systems
- C07D 498/08: Bridged systems
- C07D 513/04: Ortho-condensed systems
- C07B 2200/05: Isotopically modified compounds, e.g. labelled
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present invention provides compounds of Formula (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.

## Claims

### Claim 1

A compound, or a pharmaceutically acceptable salt thereof, selected from:

### Claim 2 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers.

### Claim 3 (depends on 1)

A combination comprising a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof and one or more therapeutically active co-agents.

### Claim 4 (depends on 1)

A method of treating a proliferative disorder selected from non-small cell lung cancer and ovarian cancer, comprising administering to a subject having said disorder a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.